| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(7 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
|
US8399015 (Pediatric) | ABBVIE INC | Solid pharmaceutical dosage form |
Feb, 2025
(1 year, 4 months from now) | |
|
US8268349 (Pediatric) | ABBVIE INC | Solid pharmaceutical dosage form |
Feb, 2025
(1 year, 4 months from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(7 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(7 years from now) | |
|
US8420596 (Pediatric) | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Oct, 2031
(8 years from now) | |
Technivie is owned by Abbvie Inc.
Technivie contains Ombitasvir; Paritaprevir; Ritonavir.
Technivie has a total of 11 drug patents out of which 0 drug patents have expired.
Technivie was authorised for market use on 24 July, 2015.
Technivie is available in tablet;oral dosage forms.
Technivie can be used as treatment of hcv infection using paritaprevir, treatment of hcv infection using ombitasvir.
The generics of Technivie are possible to be released after 13 April, 2032.
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir
Dosage: TABLET;ORAL
TECHNIVIE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic